LifeOS Genomics

Executive Summary

LifeOS Genomics is a Taiwanese biotech/IVD company commercializing a novel multiplex digital PCR (mdPCR) platform, the QLoci System, for ultra-sensitive liquid biopsy diagnostics. Founded in 2020 and headquartered in Hsinchu, the company addresses key unmet needs in oncology (e.g., early detection and monitoring of circulating tumor DNA), prenatal screening (e.g., non-invasive prenatal testing for chromosomal aneuploidies), and infectious disease monitoring (e.g., viral load quantification). Its proprietary mdPCR technology enables high‑multiplex, high‑precision quantification of genetic alterations from a simple blood draw, offering advantages in sensitivity, throughput, and cost over traditional qPCR and NGS-based methods. The company has reached the commercial stage and markets its platform and test kits primarily in Asia, with potential for global expansion. With a strong IP portfolio and a focus on scalable manufacturing, LifeOS Genomics is positioned to capture share in the rapidly growing liquid biopsy market, projected to exceed $15 billion by 2030. Its ability to serve multiple high‑value indications with a single platform differentiates it from single‑disease competitors.

Upcoming Catalysts (preview)

• Q4 2026CE-IVD marking or Taiwan FDA approval for flagship oncology liquid biopsy panel70% success
• Q3 2026Strategic partnership with a major diagnostics distributor in Southeast Asia60% success
• Q2 2026Publication of clinical validation data for prenatal screening application in a peer-reviewed journal75% success